我們已在上線！進一步了解

Pfizer

PFE

市值 US$1686億

29.58 USD

+0.14

0.48%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

29.58

0.00

0%

1天

0.48%

5天

4.08%

1個月

7.72%

3個月

17.66%

6個月

8.67%

今年迄今

17.47%

1年

22.08%

5年

-28.41%

10年

-4.05%

關於： Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

員工： 75,000

醫療保健藥品製造商－一般

新聞

正面

中性

負面

市場情緒 3個月

正面 54%

中性 30.1%

負面 15.9%

The Motley Fool

Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?

The drugmaker faces significant patent cliffs this year and next. But it also has a robust pipeline of new drugs in development.

Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?

24/7 Wall Street

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide among vaccine developers.

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

24/7 Wall Street

Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put

Profit taking is hitting one of biotech's hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 10% to $214.

Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put

24/7 Wall Street

Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher

Healthcare is drawing fresh buying as money moves away from the market's popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are up 6% to $239.

Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher

The Motley Fool

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's newer drugs are growing fast enough to more than replace Humira revenue. The hardest part of the transition appears to be behind it.

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Pfizer, Thermo Fisher Scientific And More: CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, picked U.S. 10 Year Treasury.

Pfizer, Thermo Fisher Scientific And More: CNBC's ‘Final Trades'

Zacks Investment Research

Pfizer (PFE) Gains As Market Dips: What You Should Know

The latest trading day saw Pfizer (PFE) settling at $29.21, representing a +2.96% change from its previous close.

Pfizer (PFE) Gains As Market Dips: What You Should Know

The Motley Fool

Forget Treasury Bonds: This 6%-Yielding Pharma Stock Pays You to Wait for Its Pipeline

Pfizer's non-COVID revenue grew 18% year over year, broadening its business well beyond its well-known vaccine. A deepening oncology pipeline, including a new partnership, could become Pfizer's next major growth engine.

Forget Treasury Bonds: This 6%-Yielding Pharma Stock Pays You to Wait for Its Pipeline

24/7 Wall Street

5 Large-Cap Giants Paying 5% and Bigger Dividends to Be Bought and Held Forever

Four of these five large-cap dividend stocks just dropped sharply, pushing their yields above 6%, but a rising yield can signal opportunity or a warning sign depending on what sits beneath the payout.

5 Large-Cap Giants Paying 5% and Bigger Dividends to Be Bought and Held Forever

Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the upcoming IDWeek 2026 congress, held in Washington, D.C., from October 21-24, 2026. Data across 12 oral presentations will showcase the Company's advancements in the prevention and treatment of infectious diseases. “At Pfizer, we address some of the most urgent challenges i.

Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026

查看新聞排名

價格圖表採用Lightweight Charts™實作